Developing Comprehensive Strategies for Managing Behaviorally Dysregulated Immune Effector Cell Associated Neurotoxicity Syndrome (ICANS) in Patients Undergoing Chimeric Antigen Receptor (CAR) T cell Therapy

Key Points

• Neurotoxicity associated with chimeric antigen receptor T cell therapy can lead to significant behavioral dysregulation, impacting patient outcomes.
• Adapting management strategies for immune effector cells is crucial in reducing neurotoxicity incidents, increasing patient recovery rates.
• Assessment of current approaches highlights the variability of responses in patients undergoing CAR T therapy, necessitating tailored interventions.
• Comprehensive strategies may enable better patient management, but further validation is needed in diverse clinical settings.